Xin Shi-Yong, Feng Xiao-Shan, Zhou Li-Qing, Sun Jun-Jun, Gao Xiao-Le, Yao Guo-Liang
Shi-Yong Xin, Department of Urology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.
World J Gastroenterol. 2014 Jun 14;20(22):6906-11. doi: 10.3748/wjg.v20.i22.6906.
To investigate the expression of microRNA-218 (miR-218) in serum from gastric cancer patients and its relationship with clinicopathological characteristics.
A total of 68 patients with pathologically diagnosed gastric cancer and 56 healthy individuals were recruited to this study. The expression of miR-218 was detected in the serum of gastric cancer patients and healthy individuals by quantitative real-time polymerase chain reaction. The clinical data were collected and analyzed by statistical software.
miR-218 was reduced significantly in the serum of gastric cancer patients compared to healthy individuals (1.15 ± 0.08 vs 0.37 ± 0.023; P = 0.026). In the gastric cancer group, serum expression of miR-218 was lower in patients with metastasis and poorly differentiated cancer compared with non-metastatic and well-differentiated cancer (0.19 ± 0.011 vs 0.45 ± 0.021, P = 0.031 and 0.21 ± 0.019 vs 0.49 ± 0.021, P = 0.025). Serum miR-218 was found to be significantly associated with gastric cancer metastasis (P = 0.003), tumor T stage (P = 0.018) and tumor grade (P = 0.012). Low serum expression of miR-218 was related to an increase in the stage of gastric cancer. The expression level of miR-218 in the serum was correlated with the 3-year survival. Ninety-seven percent of patients with a high level of miR-218 expression survived for 3 years, while only 54% of those with low miR-218 expression survived.
miR-218 is deregulated in gastric cancer patients and is strongly correlated with tumor stage, grade and metastasis. Serum expression of miR-218 may be a prognostic marker.
研究微小RNA-218（miR-218）在胃癌患者血清中的表达及其与临床病理特征的关系。
本研究共纳入68例经病理诊断的胃癌患者和56例健康个体。采用定量实时聚合酶链反应检测胃癌患者和健康个体血清中miR-218的表达。收集临床资料并使用统计软件进行分析。
与健康个体相比，胃癌患者血清中miR-218显著降低（1.15±0.08 vs 0.37±0.023；P = 0.026）。在胃癌组中，发生转移和低分化癌患者血清中miR-218的表达低于未发生转移和高分化癌患者（0.19±0.011 vs 0.45±0.021，P = 0.031；0.21±0.019 vs 0.49±0.021，P = 0.025）。血清miR-218与胃癌转移（P = 0.003）、肿瘤T分期（P = 0.018）和肿瘤分级（P = 0.012）显著相关。血清miR-218低表达与胃癌分期增加有关。血清中miR-218的表达水平与3年生存率相关。miR-218高表达的患者中有97%存活3年，而miR-218低表达的患者中只有54%存活。
miR-218在胃癌患者中表达失调，与肿瘤分期、分级和转移密切相关。血清miR-218表达可能是一种预后标志物。
